Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrole SCHEMBL8630353 | 0.91 | EGLN3 (0.47) | EGLN3HPGDTSHRMEN1KMT2A | |
| SCHEMBL1278389 | 0.85 | TBXAS1 (0.48) | EGLN3HPGDTSHRMEN1KMT2A | |
| SCHEMBL5512391 | 0.83 | TBXAS1 (0.56) | TSHRLMNAFABP4FABP5 | |
| SCHEMBL608651 | 0.81 | TBXAS1 (0.59) | TSHRLMNAFABP4FABP5MAPT | |
| SCHEMBL31016264 | 0.81 | TBXAS1 (0.59) | TSHRLMNAFABP4FABP5MAPT | |
| SCHEMBL5829664 | 0.81 | TBXAS1 (0.59) | TSHRLMNAFABP4FABP5MAPT | |
| SCHEMBL2287581 | 0.81 | TBXAS1 (0.59) | TSHRLMNAFABP4FABP5MAPT | |
| SCHEMBL1960855 | 0.80 | TBXAS1 (0.58) | TSHRLMNAFABP4FABP5MAPT | |
| SCHEMBL6333046 | 0.77 | LMNA (0.44) | HPGDTSHRMEN1KMT2ALMNA | |
| SCHEMBL22035378 | 0.75 | CYP1A2 (0.45) | EGLN3HPGDTSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615559-B1 | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF | UNIV NEWCASTLE (GB) | 2025-06-18 | — | — | EP | claimed |
| CN-119816735-A | Methods and assays for secretory proteome activity analysis | 康巴乔有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-20240012011-A1 | METHODS AND ASSAYS FOR SECRETOME ACTIVITY ANALYSIS | OXFORD FINANCE LLC | 2024-01-11 | — | — | US | claimed |
| CN-115245804-A | Device and process for improving reaction rate of azolepropanoic acid | 甘肃联凯生物科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-115057829-A | Synthesis method of high-purity azolepropanoic acid | 甘肃联凯生物科技有限公司 | 2022-09-16 | — | — | CN | claimed |
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-04-27 | — | — | US | claimed |
| CN-112480141-A | Pyranocoumarin derivative and preparation method and application thereof | 吉林大学珠海学院 | 2021-03-12 | — | — | CN | claimed |
| EP-3615559-A1 | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF | University of Newcastle Upon Tyne (GB) | 2020-03-04 | — | — | EP | claimed |
| CN-108743980-A | A kind of folate-targeted visualization photo-thermal-chemotherapeutant and preparation method thereof | 重庆医科大学 | 2018-11-06 | — | — | CN | claimed |
| WO-2018197873-A1 | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2018-11-01 | — | — | WO | claimed |
| EP-2049156-B1 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | CLEVELAND CLINIC FOUNDATION (US) | 2013-09-25 | — | — | EP | claimed |
| US-20120230996-A1 | Compositions And Methods For Macular Degeneration | The Cleveland Clinic Foundation and Case Western Reserve University (US) | 2012-09-13 | — | — | US | claimed |
| US-20100143380-A1 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | CLEVELAND CLINIC FOUNDATION, THE | 2010-06-10 | — | — | US | claimed |
| CN-100577283-C | Method for preparing poly-N-2-carboxyethyl pyrrole metallic chelate nano-tube used as affinity adsorbing medium | UNIV XIAMEN | 2010-01-06 | — | — | CN | claimed |
| US-20090155243-A1 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2009-06-18 | — | — | US | claimed |
| EP-2049156-A2 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | The Cleveland Clinic Foundation (US) | 2009-04-22 | — | — | EP | claimed |
| CN-101293199-A | Method for preparing poly-N-2-carboxyethyl pyrrole metallic chelate nano-tube used as affinity adsorbing medium | UNIV XIAMEN (CN) | 2008-10-29 | — | — | CN | claimed |
| WO-2008013797-A2 | COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION | THE CLEVELAND CLINIC FOUNDATION (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2007127151-A2 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2007-11-08 | — | — | WO | claimed |
| US-5766934-A | Chemical and biological sensors having electroactive polymer thin films attached to microfabricated devices and possessing immobilized indicator moieties | ALLAGE ASSOCIATES, INC. | 1998-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987408-B2 | Compositions and methods for modulating toll-like receptor 2 activation | TLR2, TLR3, TLR1 | EGLN3 1118/4885HPGD 1794/4885TSHR 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.